Patients with EGFR-mutant NSCLC BrM treated with SRS followed by EGFR-tyrosine kinase inhibitor (TKI) vs WBRT followed by EGFR-TKI vs EGFR-TKI followed by SRS or WBRT at intracranial progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.